Melanoma Therapeutics Foundation

Clinical Trials Scan Clinical Trials Scan

Melanoma Patient Forum Melanoma Patient Forum

About Us What is Melanoma? Drug Development Process Patient Information Join Us Contact Us Home

Harold A. Ellis, Jr.

Sally Park

Nils Behnke, Ph.D.

Frank McCormick, Ph.D., F.R.S.

 

Melanoma Therapeutics Foundation - Board of Directors

Harold A. Ellis, Jr.
Managing Principal, Ellis Partners, LLC

Chairman of the Board of Directors of the Melanoma Therapeutics Foundation

Harold Ellis is the President of Ellis Partners LLC. Formed in 1993 and based in San Francisco, Ellis Partners is a developer of and investor in office, industrial, retail and mixed use real estate projects located in the Western United States.

Prior to forming Ellis Partners, Mr. Ellis was the co-founder and CEO of Grubb & Ellis Company, a global diversified real estate service company with offices in all the major markets in the United States. Grubb & Ellis is one of the largest firms in this industry and is listed on the New York Stock Exchange. Mr. Ellis left Grubb & Ellis in 2002 and co-founded Ellis Partners in 1993.

Mr. Ellis has spent his entire business career in the real estate industry and is recognized as a leader in the industry having served on the boards of several real estate related companies and various industry associations.

Mr. Ellis graduated from the University of California at Berkeley and received an M.B.A. from the Stanford Graduate School of Business.

(return to top)
Sally Park

Executive Director of the Melanoma Therapeutics Foundation and Member of the Board of Directors

In addition to serving as the Executive Director of the Melanoma Therapeutics Foundation, Sally Park is the founder/owner of Sage Solutions Llc., a consulting firm which helps small and medium sized business accelerate growth by defining and implementing revenue growth strategies, building market awareness and expanding marketing reach, streamlining service delivery processes, planning events, and providing tools to measure results. Clients range from established Professional Services firms to Wellness Centers. Prior to launching Sage Solutions, Ms. Park worked in Senior Management roles for Systems Integrators and Management Consulting firms including M Squared, Inc. and Accenture.

Ms. Park earned her BA in Economics from University of California, Berkeley, and is active with many health related ventures and boards, with a foundational knowledge in yoga and meditation instruction, and their beneficial impact on health and wellness.

(return to top)
Nils Behnke, Ph.D.

Member of the Board of Directors of the Melanoma Therapeutics Foundation

Mr. Behnke is a Partner in Bain & Company’s San Francisco office. He is a member of the firm’s global healthcare practice and an expert on biotechnology and specialty pharmaceuticals. At Bain, Mr. Behnke serves biotech and pharma clients on a variety of topics, including portfolio, licensing and acquisition strategies and processes; R&D process optimization, discovery and development services and capability sourcing; product and franchise full potential (clinical development/positioning) and commercial optimization (including re-launches, sales force sizing/effectiveness, pricing strategies); and performance improvement (revenue enhancement, cost reduction, organizational and process optimization).

Besides pharma and biotech companies, Mr. Behnke has consulted clients in other sectors of life sciences, including diagnostics, discovery and development services, specialty drug providers and biotech/pharma investors.

Mr. Behnke joined Bain in early 2004, after having spent four years as CEO of a biopharmaceutical company focused on oncology. In this capacity, he managed the product development of a monoclonal antibody through phase I/II as well as the outlicensing of the antibody to a pharma partner for phase III development.

Mr. Behnke has four years of prior consulting experience as an Engagement Manager with McKinsey’s Pharmaceutical and Medical Products Practice.

He holds a Ph.D. magna cum laude and an M.A. (ranked first) from the University of Cologne in Germany.

(return to top)
Frank McCormick, Ph.D., F.R.S.

Member of the Board of Directors and Chairman of the Scientific Advisory Board of the Melanoma Therapeutics Foundation

Dr. McCormick is the Director of the University of California, San Francisco (UCSF) Comprehensive Cancer Center, designated by the National Cancer Institute (NCI, part of the National Institutes of Health) and Cancer Research Institute, a multidisciplinary research and clinical care organization that is one of the largest matrix cancer centers in the Western United States. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996.

Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92. In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996.

Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the development of novel therapeutic strategies. In addition to his position as director of the UCSF Cancer Center, Frank McCormick holds the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of more than 243 scientific publications.

Melanoma Therapeutics Foundation

Your Donation Helps

Melanoma Therapeutics Foundation
Copyright © 2008
Contact Us